brentuximab vedotin

Related by string. Brentuximab vedotin * : brentuximab vedotin SGN . brentuximab / : Brentuximab Vedotin SGN * candidate brentuximab vedotin . commercialize brentuximab vedotin . brentuximab vedotin pivotal *

Related by context. All words. (Click for frequent words.) 66 AP# [003] 65 carfilzomib 65 perifosine 64 aflibercept 64 ofatumumab 64 enzastaurin 64 deforolimus 64 satraplatin 63 FOLOTYN 63 registrational 63 ixabepilone 63 VELCADE 63 PXD# 63 valopicitabine 63 ZEVALIN 62 ganetespib 62 ridaforolimus 62 pralatrexate 62 glufosfamide 62 refractory Hodgkin lymphoma 62 Panzem R NCD 62 tanespimycin 62 ASA# 62 eniluracil 62 MGCD# [001] 62 Marqibo 62 INCB# [001] 62 T DM1 61 lintuzumab 61 picoplatin 61 VEGF Trap 61 Telaprevir 61 Taxotere ® 61 elotuzumab 61 celgosivir 61 dacetuzumab 61 Amrubicin 61 clofarabine 61 forodesine 61 ponatinib 61 L BLP# 61 Dacogen injection 61 CoFactor 61 Targretin 60 Zerenex 60 HGS ETR1 60 sapacitabine 60 blinatumomab 60 HuMax EGFr 60 HGS# 60 bendamustine 60 obatoclax 60 Ixempra 60 adecatumumab 60 alvespimycin 60 brentuximab vedotin SGN 60 Azedra 60 CR# vcMMAE 60 RG# [001] 60 BAY #-# 60 OPAXIO 60 Cloretazine R VNP#M 60 Nexavar 60 custirsen 60 Phase Ib 60 TORISEL 60 RITUXAN 60 pertuzumab 60 Amigal 60 Taxotere R 60 L MTP PE 60 Vectibix 60 panitumumab 60 YONDELIS 60 LEVADEX 59 ularitide 59 albinterferon alfa 2b 59 NVA# 59 TREANDA 59 voreloxin 59 imetelstat 59 CIMZIA TM 59 SAR# [004] 59 oral ridaforolimus 59 BEXXAR 59 IMGN# 59 Cladribine Tablets 59 IIa trial 59 TOCOSOL Paclitaxel 59 docetaxel Taxotere R 59 BLA filing 59 SPRYCEL ® 59 INCB# [002] 59 Perifosine 59 ocrelizumab 59 Nexavar ® 59 pemetrexed 59 FTY# 59 peginesatide 59 gefitinib 59 dose escalation 59 registrational trial 59 ambrisentan 59 evaluating tivozanib 59 Allovectin 7 59 Tarceva TM 59 Tarceva 59 Neulasta ® 59 SUCCEED trial 59 Phase Ib II 58 Onco TCS 58 relapsed multiple myeloma 58 phase IIb clinical 58 axitinib 58 monotherapy 58 Genasense 58 Fludara 58 Allovectin 7 R 58 TRISENOX 58 OLEPTRO TM 58 alvimopan 58 palifosfamide 58 OMAPRO 58 PEG SN# 58 ERBITUX 58 dasatinib 58 methylnaltrexone 58 RGB # 58 HuMax CD4 58 temozolomide 58 Bortezomib 58 tamibarotene 58 bortezomib 58 REOLYSIN ® 58 talactoferrin 58 oxymorphone ER 58 mipomersen 58 Allovectin 7 ® 58 HER2 positive metastatic breast 58 Phase 1b trial 58 GATTEX 58 QUADRAMET 58 BCX# 58 Traficet EN 58 Velcade 58 Genasense ® 58 eculizumab 58 Actemra 58 AeroLEF TM 58 vandetanib 58 nab paclitaxel 58 sunitinib malate 58 neratinib 58 TELCYTA 58 nimotuzumab 57 Xcytrin 57 Zevalin 57 atacicept 57 ISENTRESS 57 Velcade bortezomib 57 UPLYSO 57 Satraplatin 57 pazopanib 57 Phase Ib study 57 OncoVEX GM CSF 57 naproxcinod 57 otelixizumab 57 KRN# 57 tezampanel 57 Phase 2a trial 57 Phenoptin 57 Troxatyl 57 Icatibant 57 Virulizin ® 57 refractory PTCL 57 XL# [003] 57 R sorafenib tablets 57 Quinamed 57 evaluating REVLIMID 57 bazedoxifene 57 belinostat 57 registrational studies 57 Jevtana 57 MoxDuo IR 57 carboplatin paclitaxel 57 MOZOBIL 57 tocilizumab 57 Herceptin trastuzumab 57 Plicera 57 ProLindac 57 elacytarabine 57 MAGE A3 ASCI 57 docetaxel chemotherapy 57 omacetaxine 57 Civacir 57 Tamibarotene 57 rituximab 57 Insegia 57 JANUVIA 57 ANA# 57 GRN#L 57 FOLOTYN ® 57 Anturol 57 afatinib 57 Ventavis 57 temsirolimus 57 Sulonex TM 57 Tekamlo 57 zalutumumab 57 IMA# 57 Dapagliflozin 57 FOLFIRI 57 Gemzar ® 57 gemcitabine 57 torezolid phosphate 57 XGEVA 57 brivaracetam 57 zileuton CR 57 docetaxel 57 cetuximab 57 ZOLINZA 57 carboplatin 57 Imprime PGG 57 Phase IIb trials 57 XYOTAX 57 vinorelbine 57 amrubicin 57 pomalidomide 57 Reolysin 57 tivozanib 57 galiximab 57 ADVEXIN 57 PEG PAL 57 JAK inhibitor 57 vidofludimus 57 phase IIb 57 RAPTIVA 56 Belinostat 56 PEG Interferon lambda 56 Onrigin 56 teriflunomide 56 daclizumab 56 AzaSite Plus 56 AEGR 56 AGGRASTAT ® 56 vemurafenib 56 HRPC 56 Tarceva erlotinib 56 MEPACT 56 dirucotide 56 Folotyn 56 mapatumumab 56 APOPTONE 56 Junovan 56 thymalfasin 56 MAA submission 56 sNDA submission 56 VIDAZA 56 Mepact 56 IRX 2 56 eltrombopag 56 FOLFOX 56 maribavir 56 sorafenib 56 phase Ib 56 dose cohort 56 elesclomol 56 Chemophase 56 KALBITOR 56 BEMA Fentanyl 56 ALN PCS 56 NDA submission 56 fidaxomicin 56 FavId 56 Vidaza 56 Phase 1b 56 ZK EPO 56 APF# 56 GALNS 56 Panzem R 56 Targretin capsules 56 Tocosol Paclitaxel 56 lurasidone 56 cediranib 56 NGX# 56 vilazodone 56 TMC# [002] 56 BYDUREON 56 Clolar ® 56 CYCLOSET 56 Zensana TM 56 PROSTVAC TM 56 Pralatrexate 56 SIMPONI 56 Omnitarg 56 ISTODAX 56 Ceplene 56 Advexin 56 CIMZIA ™ 56 Clolar 56 GSK# [001] 56 Erbitux 56 Alocrest 56 DU #b 56 Vilazodone 56 posaconazole 56 clevudine 56 BiovaxID 56 MBP# [001] 56 follicular NHL 56 refractory CTCL 56 velafermin 56 Panzem 56 OXi# 56 Azixa 56 telaprevir 56 Pirfenidone 56 EOquin TM 56 Plenaxis R 56 HuLuc# 56 teduglutide 56 apaziquone 56 oral rivaroxaban 56 RhuDex ® 56 CD# antibody [001] 56 BENLYSTA 56 tesmilifene 56 sunitinib 56 refractory chronic lymphocytic 56 Virulizin R 56 ZEGERID Capsules 56 PDX pralatrexate 56 PEG INTRON 56 Asentar 56 sorafenib tablets 56 Bezielle 56 dose escalation trial 56 PANVAC VF 56 evaluating satraplatin 55 MLN# 55 LymphoStat B 55 Rituxan 55 Rhucin 55 PREOS R 55 denosumab 55 velaglucerase alfa 55 Cloretazine R 55 TMC# [001] 55 veltuzumab 55 Bicifadine 55 TYKERB 55 TNFerade 55 HGS ETR2 55 MabThera rituximab 55 fipamezole 55 azacitidine 55 Archexin 55 Copegus ribavirin 55 bicifadine 55 trabectedin 55 golimumab 55 BRAF inhibitor 55 Rituximab 55 Taxotere docetaxel 55 cetrorelix 55 Phase IIIb clinical 55 MabCampath 55 BrachySil TM 55 Viramidine 55 adalimumab 55 palonosetron 55 pegfilgrastim 55 Serdaxin 55 sorafenib Nexavar ® 55 metaglidasen 55 THALOMID 55 Phase 2b clinical 55 ELACYT 55 LUMINATE 55 Avastin bevacizumab 55 Santhera 55 nonclinical studies 55 rALLy clinical trial 55 randomized Phase 55 oral deforolimus 55 PREOS 55 MyVax R 55 AVADO 55 Restanza 55 rALLy trial 55 BEMA TM Fentanyl 55 Panitumumab 55 gefitinib Iressa 55 standard chemotherapy regimen 55 Sandostatin LAR Depot 55 ruxolitinib 55 MDV# 55 Ceflatonin 55 Genasense R 55 NEUVENGE 55 PRECiSE 55 Phase 2a 55 Revlimid lenalidomide 55 Cloretazine ® 55 Corlux 55 severe hypercholesterolemia 55 Firazyr 55 VPRIV 55 #D#C# 55 APPRAISE 55 oral FTY# 55 SILENOR TM 55 EndoTAG TM -1 55 ABRAXANE 55 PSMA ADC 55 MabThera 55 antitumor activity 55 IMC A# 55 telavancin 55 Phase IIb 55 zanolimumab 55 HuMax CD# 55 TELINTRA 55 Phase IIb trial 55 Celgene Revlimid 55 AZOR 55 Pimavanserin 55 NSABP 55 bardoxolone 55 bevacizumab Avastin ® 55 OvaRex R 55 ALIMTA 55 exenatide once 55 Phase #b/#a 55 Phase IIa trials 55 IRESSA 55 platinum refractory 55 HCV protease inhibitor 55 maximally tolerated dose 55 LAF# 55 XL# XL# XL# XL# 55 acyclovir Lauriad R 55 Mozobil 55 hematologic malignancies 55 telbivudine 55 relapsed refractory multiple myeloma 55 IMC #B 55 phase IIa clinical 55 zoledronic acid 55 PROMACTA 55 paclitaxel Taxol ® 55 huC# DM4 55 BRIM2 55 plus dexamethasone 55 RDEA# 55 SUTENT 55 metastatic hormone refractory 55 Fibrillex TM 55 Trastuzumab 55 Phase 2b trial 55 evaluating T DM1 55 Afinitor 55 motesanib 55 lorvotuzumab mertansine 55 PrevOnco 55 RECOTHROM 55 Antegren 55 OncoVEX 55 Sprycel 55 Stimuvax R 55 initiate Phase Ib 55 SNT MC# 55 treprostinil 55 Tavocept 55 randomized Phase III 55 ISIS # 55 LY# [003] 55 romidepsin 55 BLA submission 55 danoprevir 55 mifamurtide 55 ipilimumab 55 PROVENGE 55 NEBIDO 55 Azilect ® 55 DASISION 55 Neurodex 55 Dacogen 55 regadenoson 55 trastuzumab DM1 55 REVLIMID 55 QVA# 55 PS# [001] 55 YERVOY 55 TACI Ig 55 metastatic colorectal cancer 55 Oxaliplatin 55 goserelin 55 Gemcitabine 55 Solasia 54 immunotherapeutic agent 54 CLARITY study 54 APD# 54 aleglitazar 54 Torisel 54 COMFORT II 54 ezogabine 54 metastatic CRC 54 dacarbazine 54 assessing T DM1 54 cetuximab Erbitux 54 plus prednisone 54 oral prodrug 54 Brentuximab Vedotin SGN 54 Fx #A 54 PRT# 54 adjuvant therapy 54 MAXY alpha 54 Naproxcinod 54 indolent NHL 54 rindopepimut 54 ACTEMRA 54 Tekturna HCT 54 FUZEON 54 HspE7 54 Catena ® 54 visilizumab 54 ProSavin 54 Urocidin 54 nalbuphine ER 54 EXPAREL ™ 54 Zelrix 54 Glufosfamide 54 lubiprostone 54 Phase III clinical 54 OvaRex ® MAb 54 investigational compound 54 lixisenatide 54 Empatic 54 tubulin inhibitor 54 vorinostat 54 Huntexil 54 REVLIMID R 54 CA4P 54 investigational humanized monoclonal antibody 54 TYZEKA 54 Elagolix 54 Locteron 54 metastatic HRPC 54 refractory multiple myeloma 54 febuxostat 54 lesinurad 54 biologic therapy 54 Combidex 54 ELOXATIN 54 abiraterone acetate 54 infusional 5-FU/LV 54 IL# PE#QQR 54 trastuzumab DM1 T DM1 54 Telcyta 54 pain palliation 54 DAVANAT 54 Hematide 54 QNEXA 54 hematological malignancies 54 ALGRX 54 Campath 54 brentuximab 54 pitavastatin 54 uric acid lowering 54 ThermoDox R 54 FOLFOX6 chemotherapy regimen 54 Bronchitol 54 EFAPROXYN 54 vosaroxin 54 Omacetaxine 54 iclaprim 54 phase IIb trial 54 oral dnaJP1 54 peg IFN 54 MAXY G# 54 sorafenib Nexavar R 54 refractory metastatic colorectal cancer 54 KNS # 54 Telavancin 54 INTEGRILIN 54 CTAP# Capsules 54 initiate Phase 1b 54 Panzem NCD 54 investigational monoclonal antibody 54 ENDEAVOR IV 54 Opexa 54 LIALDA 54 edoxaban 54 TEMODAL 54 cinacalcet HCl 54 Adlea 54 sunitinib Sutent 54 TASQ 54 multiple myeloma MM 54 pemetrexed Alimta 54 PI3K/Akt pathway inhibitor 54 ONCASPAR 54 ONCONASE 54 relapsed SCLC 54 rNAPc2 54 TRO# 54 follicular non 54 PHX# 54 ASONEP 54 ARIKACE 54 Loramyc ® 54 hoFH 54 Fodosine 54 limiting toxicity 54 Trofex 54 viral kinetic 54 almorexant 54 eprotirome 54 DPX Survivac 54 ThermoDox ® 54 panitumumab Vectibix 54 pegylated interferon alfa 2b 54 Aflibercept 54 refractory AML 54 confirmatory Phase 3 54 GVAX immunotherapy 54 ascending dose 54 Neuradiab 54 TKM ApoB 54 dextromethorphan quinidine 54 Ereska 54 MONOVISC 54 oral calcitonin 54 Teysuno 54 subcutaneous formulation 54 Fludara ® 54 Phase III pivotal 54 trastuzumab 54 pixantrone 54 PRISTIQ 54 mertansine 54 ALN TTR 54 cutaneous T cell 54 Exforge 54 Cimzia TM 54 antibody MAb 54 IAP inhibitors 54 pegloticase 54 Pazopanib 54 HCD# [002] 54 AZILECT R 54 atrasentan 54 Aurexis 54 bevacizumab 54 R#/MEM # 54 Xcellerated T Cells 54 Entereg R 54 placebo controlled clinical 54 Phase 2b study 54 taribavirin 54 Proxinium TM 54 Benlysta belimumab 54 Nanobody 54 Navelbine ® 54 UVIDEM 54 Triapine 54 diabetic neuropathic pain 54 Rhucin ® 54 voclosporin 54 Lodotra 54 dose escalation Phase 54 oral methylnaltrexone 54 ACTEMRA TM 54 alogliptin 54 Sym# 54 Hycamtin ® 54 Phase 2b 54 crizotinib PF # 54 gemcitabine carboplatin 54 orBec R 54 Campath alemtuzumab 54 tolerability 54 IV APAP 54 ustekinumab 54 Raptiva ® 54 Ofatumumab 54 Evoltra ® 54 tesetaxel 54 PEGINTRON 54 Soliris 54 Diamyd ® 54 tasimelteon 54 decitabine 54 ThermoDox 54 Aplidin 54 CAELYX 53 COPEGUS 53 proteasome inhibitor 53 ATL# [001] 53 ZADAXIN 53 refractory APL 53 Xelox 53 bafetinib 53 HERmark 53 cilengitide 53 pegylated interferons 53 Pivotal Phase III 53 tolerability profiles 53 receptor tyrosine kinase inhibitor 53 TLK# 53 romiplostim 53 NUVIGIL 53 REOLYSIN R 53 TTF Therapy 53 Defibrotide 53 nilotinib 53 neoadjuvant treatment 53 Clofarabine 53 OHR/AVR# 53 docetaxel Taxotere 53 samalizumab 53 INT# [002] 53 GATTEX TM 53 SILENOR 53 AQ4N 53 ongoing Phase 1b 53 Keppra R 53 Treanda 53 Northera 53 lumiliximab 53 RAD# [003] 53 bosutinib 53 MGd 53 taxane 53 Rituxan rituximab 53 dimebon 53 COPAXONE R 53 Stedivaze 53 LEP ETU 53 PegIntron 53 RSD# iv 53 Arzerra ofatumumab 53 Abiraterone acetate 53 eprodisate Fibrillex TM 53 DOXIL 53 Elotuzumab 53 Cleviprex TM clevidipine 53 Carfilzomib 53 taliglucerase alfa 53 bone metastases 53 RSD# oral 53 Marketing Authorization Application 53 Lialda 53 ELND# 53 rilpivirine 53 resminostat 53 LEVADEX ™ 53 Folfox 53 bevacizumab Avastin 53 Mylotarg 53 Alpharadin 53 CRMD# 53 LymphoStat B belimumab 53 chlorambucil 53 FRDA 53 BEMA Buprenorphine 53 paclitaxel poliglumex 53 rilonacept 53 initiate Phase IIb 53 Immunotherapeutic 53 Abraxane 53 Azedra TM 53 ANYARA 53 Pixuvri 53 thalidomide Thalomid 53 metastatic GIST 53 vicriviroc 53 Augment Injectable 53 OFIRMEV 53 Keppra ® 53 Hycamtin 53 Kuvan 53 docetaxel Taxotere ® 53 laquinimod 53 TYSABRI 53 INTEGRILIN ® 53 Tasigna 53 Cethrin 53 PIX# [002] 53 CD# CEA 53 Cinryze 53 Oncoscience AG 53 AGILECT R 53 mGluR5 negative 53 Albuferon 53 PROVENGE ® 53 CCX# 53 iloperidone 53 INTEGRILIN R eptifibatide Injection 53 linaclotide 53 Denosumab 53 PhosLo 53 Alemtuzumab 53 Voraxaze ™ 53 Genentech Roche 53 Gabapentin GR 53 Rhucin R 53 active comparator 53 Phase IIa clinical 53 Intravenous CP 53 Solazed 53 Azedra ™ 53 Revlimid 53 relapsed MCL 53 BiTE antibody 53 BRIM3 53 Phase IIa trial 53 orBec 53 Vectibix panitumumab 53 EOquin 53 trastuzumab emtansine T DM1 53 Alzhemed TM 53 lenalidomide Revlimid R 53 aflibercept VEGF Trap 53 Xanafide 53 Targeted Chemotherapy 53 MEK inhibitor RDEA# 53 Vitaxin 53 aplindore 53 indiplon capsules 53 dapagliflozin 53 relapsed myeloma 53 heavily pretreated 53 Rebif ® 53 angiogenesis inhibitor 53 vernakalant oral 53 personalized immunotherapy 53 oral taxane 53 farletuzumab 53 Vandetanib 53 dose cohorts 53 ANTEGREN 53 Fampridine SR 53 Intermezzo R 53 Phase III trials 53 ApoB SNALP 53 SABCS 53 AZD# 53 liposomal formulation 53 pivotal Phase 53 Ambrisentan 53 Erlotinib 53 sapacitabine CYC# 53 riociguat 53 reslizumab 53 Laquinimod 53 Topical Interferon Alpha 2b 53 Pruvel 53 Vicinium TM 53 Delcath PHP System 53 glatiramer acetate 53 bortezomib Velcade 53 MuGard 53 Abiraterone 53 NP2 Enkephalin 53 Telatinib 53 confirmatory Phase III 53 Camptosar 53 exenatide 53 PROPEL trial 53 Phase #/#a trial 53 Orathecin 53 Phase IIb clinical 53 seliciclib 53 Soliris TM eculizumab 53 Prestara 53 Gleevec Glivec 53 EGFR expressing mCRC 53 dacetuzumab SGN 53 abatacept 53 TRV# [001] 53 Cutaneous T 53 Biologics License Application BLA 53 Revimmune 53 ORENCIA ® 53 tipranavir 53 FOLFOX4 53 follicular Non Hodgkin 53 relapsed refractory 53 oncology indications 53 POSIDUR 53 MEK inhibitors 53 ATryn R 53 Æterna Zentaris 53 Dyloject TM 53 low dose cytarabine 53 Symadex 53 Phase III 53 QAB# 53 Hematological Malignancies 53 sNDA 53 NPSP# 53 recurrent NSCLC 53 PF # [001] 53 IPX# 53 Doxil 53 Eloxatin ® 53 etanercept 53 T Pred 53 sorafenib Nexavar 53 Roche Chugai s 53 lacosamide 53 CRLX# 53 Phase IIa 53 AVE# 53 CUBICIN 53 Ceflatonin R 52 briakinumab 52 NXL# 52 radiation sensitizer 52 cathepsin K inhibitor 52 iniparib 52 EndoTAGTM 1 52 ONTAK 52 oxaliplatin 52 pradefovir 52 adjuvant GIST 52 Pertuzumab 52 paclitaxel Taxol 52 lintuzumab SGN 52 incyclinide 52 anti EGFR antibody 52 PSN# [002] 52 Solazed TM 52 Reclast Aclasta 52 erlotinib Tarceva ® 52 pivotal Phase III 52 Aclasta 52 PROVIGIL 52 phase IIa 52 surrogate endpoint 52 metastatic renal cell 52 EGRIFTA TM 52 NUEDEXTA 52 Zenvia ™ 52 TRANSDUR Sufentanil 52 evaluating Xcytrin 52 Exherin TM 52 MEND CABG II 52 YONDELIS R 52 elagolix 52 RAPTIVA R 52 Stalevo 52 ILLUMINATE 52 oral anticoagulant 52 TASKi3 52 Triapine R 52 integrase inhibitor 52 FOLPI 52 Betaferon ® 52 Phase IIb clinical trials 52 plus gemcitabine 52 elinogrel 52 Hepatocellular Carcinoma HCC 52 XmAb# 52 AZILECT ® 52 Dalbavancin 52 neoadjuvant 52 AEG# 52 prGCD 52 DPP4 inhibitor 52 metastatic renal cell carcinoma 52 GetGoal Phase III 52 irbesartan 52 trastuzumab Herceptin R 52 alemtuzumab Campath 52 telaprevir VX 52 JAK2 inhibitor 52 Tygacil 52 Pegasys ® 52 systemic ALCL 52 PRX # 52 BCIRG 52 RSD# 52 Phase IIB 52 Evoltra TM 52 clevidipine 52 HCV protease inhibitors 52 GVAX 52 INTELENCE 52 Dasatinib 52 ozarelix 52 Phase IIa clinical trials 52 Acetavance 52 MGCD# [002] 52 velafermin belinostat 52 ZACTIMA 52 PDE4 inhibitor

Back to home page